News Article | April 18, 2017
(PRLEAP.COM) April 18, 2017 - One of Grand Rapids newest apartment communities, The Gateway at Belknap, will feature Spartan Net's Ultra High Speed Spartan Fiber Internet service for its residents.Spartan Net announced that 1-Gigabit Internet service has been fully deployed at the new development. The 1,000 Mbps Internet service means faster downloads, less buffering, and an ultra-reliable connection. You can download your favorite 90-minute HD movie in as little as 34 seconds.According to the National Multifamily Housing Council, when considering where to live, renters rank high speed Internet higher than amenities like a pool or a fitness center. The Spartan Fiber Internet service is available at apartment communities throughout Downtown Grand Rapids. Apartments with Grand Rapids fiber Internet service can be found using Spartan Net's apartment fiber locator.The Gateway at Belknap Apartments are located in the Belknap Lookout neighborhood overlooking the Medical Mile, which includes Michigan State University's College of Human Medicine, Spectrum Health's downtown hospital campus, the Van Andel Research Institute and Grand Valley State University's Cook-DeVos Center for Health Sciences.Residents also have access to Spartan Net powered community Wi-Fi which allows connection to any other Spartan Net Wi-Fi location. "They love it," said Richard Laing, Chief Operating Officer of Spartan Net, "It's the best Internet you can get, up to 100 times faster than cable and its here now."The Gateway at Belknap development is located at:513 Clancy Avenue NEGrand Rapids, MI 49503In addition to ultra-fast Internet, residents have access to DIRECTV apartment TV services featuring over 315 channels. Spartan Net is an alternative to the big cable companies with same day local service, free install and no service call fees.To find your fiberhood, visit https://www.spartan-net.com/high-speed-fiber-internet.html About Spartan Net Co.Spartan Net is a Michigan-based, privately owned Internet Service Provider that specializes in Ultra Fast 1-Gigabit Internet and TV solutions for Multi-Family communities of all sizes. Spartan Net understands the unique needs of property owners and goes above and beyond typical apartment Internet service providers.
News Article | May 4, 2017
WALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE MKT: CVRS) announced today that it will be participating in the SCAI 2017 Scientific Sessions to be held May 10-13 in New Orleans, LA. Robotic-assisted percutaneous coronary intervention (PCI) will be featured throughout the conference, including in the exhibit hall, presentations, and during a lunch symposium. SCAI attendees are invited to register for the educational lunch symposium entitled "The Next Generation of Cath Lab Robotics" sponsored by Corindus on Friday, May 12 from 12:15 - 1:15pm. The symposium, chaired by Ehtisham Mahmud, MD, FSCAI of UC San Diego School of Medicine, will also feature faculty and key robotic physicians Ryan Madder, MD, Frederick Meijer Heart & Vascular Institute, Spectrum Health, and Paul Campbell, MD, Carolinas HealthCare System NorthEast. Audience Q&A and discussion will follow the symposium presentations. Symposium Chairman Ehtisham Mahmud, MD, stated, "I look forward to sharing how robotic PCI can be incorporated to the contemporary practice of interventional cardiology. Recent advancements in the CorPath technology platform have been transformational and I am enthusiastic about the future of robotics in the treatment of complex coronary disease." The symposium will feature the following topics: Space for the lunch symposium is limited; registration is available at www.corindus.com/SCAI2017. During the conference, Dr. Mahmud will also present study data from the PRECISION Registry as a Late Breaking Clinical Trial. In addition to educational opportunities to learn more about robotics, the CorPath GRX System will be on display in Corindus' Booth 304. To schedule a hands-on demonstration of robotic-assisted PCI with an advanced simulator, please visit www.corindus.com/SCAI2017. Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath® System is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary interventions. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program." For additional information, visit www.corindus.com, and follow @CorindusInc. Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Corindus’ control. An example of such a statement is about the future of robotics in treatment of complex artery disease. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled "Risk Factors" in the company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, including, but not limited to the following: the rate of adoption of our CorPath System and the rate of use of our cassettes; risks associated with market acceptance, including pricing and reimbursement; our ability to enforce our intellectual property rights; our need for additional funds to support our operations; our ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend our sales; and the effect of credit, financial and economic conditions on capital spending by our potential customers. Forward looking statements speak only as of the date they are made. Corindus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date. More information is available on Corindus' website at http://www.corindus.com.
News Article | May 17, 2017
Attendees span the leading payers and providers, systems and hospitals, urban and rural delivery system organization across all provider types and all payer lines of business including representatives from Abbeville General Hospital, Anthem BlueCross BlueShield, Baptist Health, BlueCross BlueShield of Michigan, BlueCross BlueShield of Minnesota, BlueCross BlueShield of North Carolina, BlueCross BlueShield of North Dakota, BlueCross BlueShield of Rhode Island, Bright Health, Independent Health, Carle, Cambia, CareMore, Carolinas HealthCare System, Centene Corporation, Central Georgia Medical Care Network, FullWell, Gateway Health, Geisinger, George Washington University, Department of Health and Human Services, Health Care Service Corporation, The Health Collaborative, Health Net, Humana, Indiana University Health, Johns Hopkins Medicine, KentuckyOne Health, Mercy, MetroHealth, Molina Healthcare, MVP Healthcare, Norton Healthcare, Navient Health, BlueCross BlueShield of Nebraska, Northwestern Medicine, Ochsner Health System, Passport Health Plan, Quartet, Quest Diagnostics, Rothman Institute, SIH Medical Group, Spectrum Health, St. Joseph Health, St. Jude Children's Hospital, Urgent Care Association of America, United Healthcare, and U.S. News and World Report. The May session of the Institute for the Delivery of High-Value Care Best Practice Vignettes cover success stories and challenges in delivering high-value care in the realistic operating environments and include the topics: "The Mandate: Payment Vs. Know-How"; "Clinician to Clinician: A High-Value Conservation"; "System Frenemies? Hospitals Vs. Groups"; "Flowing Downhill: PCPs Vs. Specialists"; "West Coast Vs. Fly-over Country"; "Mandate: Market and Momentum"; "Clinician to Clinician: High-Value Hang Ups and Solutions"; "Tying the Knot: High-Value Care Model as a Payer Strategic Advantage"; "Commercial Vs. Government Programs"; and "The Tactics: Competition Vs. Tough Cultures". Interactive Game-Based Workshops feature payers and providers across functional areas working together to better understand, communicate and operationally support the delivery of high-value care and include the topics: "Moneyball: An MBA for Healthcare"; "Comm. 101: Culture and Consensus"; "Clinicians to Clinicians: Behind Closed Doors"; "Comm. 101: Talking to Physicians"; "Translation: Talking to Clinicians"; "Comm. 101: Talking to Actuaries"; "Comm. 101: Talking to Analysts"; "Healthcare and/Vs. High-Performing Leadership"; "Hot Takes and Trends: Real Vs. Hype"; "Behind Closed Doors: Clinicians to Clinicians"; "Comm. 101: Talking to Your ELT"; "Comm. 101: Talking to Sales"; and "Pulling This All Together: What Are We Doing Here and What Are You Going to Do About It on Monday." For more information, please see https://instituteofhighvaluecare.org/. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/leaders-across-the-country-embark-on-high-value-care-with-the-institute-for-the-delivery-of-high-value-care-300458766.html
News Article | May 17, 2017
GRAND RAPIDS, Mich., May 17, 2017 /PRNewswire-USNewswire/ -- Every summer, approximately 2.7 million children in the US ages 14 and under are treated in emergency rooms for accidental injuries. Injury prevention experts at Spectrum Health in Grand Rapids, Michigan say more children are accidentally injured during the summer months than any other time of year. Injury Prevention Specialist Jennifer Hoekstra shares the following tips for families kicking off the summer season:
News Article | May 26, 2017
May 26, 2017 - Skull fractures and other head and facial injuries from motorcycle trauma in Michigan have doubled since that state relaxed its motorcycle helmet laws, reports a study in the June issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS). The new study is one of the first to focus on how helmet laws affect CMF trauma rates. "Our study demonstrates the negative impact of weakened motorcycle helmet laws leading to decreased helmet use," said lead author Nicholas S. Adams, MD, of Michigan State University College of Human Medicine and Spectrum Health, Grand Rapids. The findings suggest that higher numbers of craniomaxillofacial (CMF) injuries can be added to increased deaths, serious injuries and health care costs when motorcyclists ride without helmets. The researchers used a state trauma quality improvement database to analyze changes in the rate of CMF injuries to motorcycle riders since the change in Michigan helmet laws. In 2012, Michigan repealed its universal motorcycle helmet law in favor of a partial law. Under the new law, riders are eligible to ride without helmets if they meet criteria for age (over 21), training/experience and insurance coverage. Trends in CMF injuries were analyzed for three years before and three years after the change in helmet laws. The study included a total of 4,643 motorcycle trauma patients seen at 29 Michigan trauma centers. Under the new law, the proportion of motorcycle trauma patients who were riding without helmets more than doubled, from 20 to 44 percent. Compared to helmeted patients, those not wearing helmets were about twice as likely to sustain CMF injuries. The difference was significant for fractures and soft tissue injuries. Patients without helmets had higher injury severity scores. Before and after the change in helmet laws, unhelmeted patients had higher blood alcohol content. The absolute rate of CMF injuries increased from 25.5 percent under the universal helmet law to 37.2 percent under the partial helmet law. This translated into a relative 46 percent increase in overall CMF injuries, including a 28 percent increase in fractures and a 56 percent increase in soft tissue injuries. The researchers also noted an increase in certain patterns of facial injuries after the change in helmet laws. Fractures of the cheekbones (malar fractures) increased significantly, as did facial lacerations, contusions and abrasions. All types of injuries were more common in unhelmeted patients. There is a long history of debate over motorcycle helmet laws. Previous studies have shown that helmets prevent nearly 40 percent of fatal injuries and 13 percent of nonfatal serious injuries. Yet, up to one-third of motorcycle riders do not wear helmets, even more in states without universal helmet laws. Dr. Adams said, "We urge state and national legislators to reestablish universal motorcycle helmet laws." Based on their findings, the researchers estimate that wearing a motorcycle helmet can decrease the risk of facial trauma by half, while requiring all riders to wear helmets could decrease facial injuries by more than 30 percent. Plastic and Reconstructive Surgery® is published by Wolters Kluwer. Click here to read "The Effects of Motorcycle Helmet Legislation on Craniomaxillofacial Injuries." Article: "The Effects of Motorcycle Helmet Legislation on Craniomaxillofacial Injuries" (doi: 10.1097/PRS.0000000000003370) For more than 70 years, Plastic and Reconstructive Surgery® (http://www. ) has been the one consistently excellent reference for every specialist who uses plastic surgery techniques or works in conjunction with a plastic surgeon. The official journal of the American Society of Plastic Surgeons, Plastic and Reconstructive Surgery® brings subscribers up-to-the-minute reports on the latest techniques and follow-up for all areas of plastic and reconstructive surgery, including breast reconstruction, experimental studies, maxillofacial reconstruction, hand and microsurgery, burn repair, and cosmetic surgery, as well as news on medico-legal issues The American Society of Plastic Surgeons is the largest organization of board-certified plastic surgeons in the world. Representing more than 7,000 physician members, the Society is recognized as a leading authority and information source on cosmetic and reconstructive plastic surgery. ASPS comprises more than 94 percent of all board-certified plastic surgeons in the United States. Founded in 1931, the Society represents physicians certified by The American Board of Plastic Surgery or The Royal College of Physicians and Surgeons of Canada. Wolters Kluwer N.V. (AEX: WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services. Wolters Kluwer reported 2016 annual revenues of €4.3 billion. The company, headquartered in Alphen aan den Rijn, the Netherlands, serves customers in more than180 countries, maintains operations in more than40 countries and employs 19,000 people worldwide. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY). For more information about our solutions and organization, visit http://www. , follow us on Twitter, Facebook, LinkedIn, and YouTube.
News Article | December 22, 2016
Portland, Oregon, Dec. 21, 2016 - The addition of bortezomib to a standard two-drug regimen for multiple myeloma patients significantly lengthened the time before their cancer returned, and significantly lengthened their lives, according to clinical trial results in The Lancet. Investigators from SWOG, the international cancer clinical trials network funded by the National Cancer Institute (NCI), compared the effectiveness of two drug regimens in newly diagnosed patients undergoing their first round of treatment for multiple myeloma, a type of bone marrow cancer. One regimen used in the study was lenalidomide with dexamethasone, a standard first-line treatment. The other drug regimen also included bortezomib, a second-line drug typically given to myeloma patients whose cancer progresses after initial therapy. SWOG researchers found that the addition of bortezomib made a significant difference for myeloma patients, giving them about another year of remission and another year of life. Patients receiving bortezomib, along with lenalidomide and dexamethasone, in their first six months of treatment had a median remission time of 43 months compared to a median remission of 30 months for patients who received lenalidomide and dexamethasone alone. Researchers also found that patients who received bortezomib lived a median of 75 months, or about six years, after their initial treatment. Patients who received the standard two-drug treatment lived a median of 64 months, or about five years, after initial treatment. "There's a lot of excitement about these research findings and this treatment option, which helps myeloma patients stay healthier longer and gives them more time to spend with people they love," said SWOG study principal investigator Brian G.M. Durie, M.D., a physician at Cedars-Sinai Outpatient Cancer Center in Los Angeles and chairman of the board at the International Myeloma Foundation. "Because the research was so solid, and the findings so strong, we're looking at a potential new standard of care." Results of the SWOG study, S0777, first gained attention in December 2015 at the 57th Annual Meeting of the American Society of Hematology (ASH) held in Orlando, Florida. Myeloma is the second most common blood cancer in the world. According to NCI statistics, in 2016 an estimated 30,330 new cases of myeloma will be diagnosed and 12,650 people will die of the disease in the U.S. In recent years, new drugs have brought new hope, and life expectancy for people diagnosed with multiple myeloma is slowly rising. SWOG researchers enrolled 471 eligible and consented adult patients in S0777 between February 2008 and February 2012 at 139 institutions throughout the National Cancer Trials Network (NCTN), the nation's oldest and largest publicly funded cancer research network. The NCTN includes SWOG, the Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group, and NRG Oncology, which all enrolled patients to S0777, as well as the Children's Oncology Group, which focuses on pediatric cancers. S0777 patients ranged in age from 28 to 87, had active myeloma, and had not had a stem-cell transplant or any prior treatment for their disease. Patients were randomized into two groups. One group received the standard two-drug treatment for six cycles over six months. That includes lenalidomide, an immunomodulating therapy marketed as Revlimid by Celegene Corporation. The other group received a three-drug combination that included bortezomib, a proteasome inhibitor marketed as Velcade by Millennium Pharmaceuticals. These patients received the triple combination therapy for eight cycles over six months. Despite the increased remission and longevity, the three-drug combination did have a drawback: Patients who received bortezomib were much more likely to experience sensory neuropathy, or tingling, pain, numbness or weakness in their hands and feet. The NCI provided primary grant funding for S0777 and was the sponsor of the study. Millennium Pharmaceuticals, Inc., The Takeda Oncology Company, and Celgene Corporation provided the study drugs under their respective Cooperative Research and Development Agreements with the NCI. A national team of SWOG researchers led S0777. Along with Durie, they include: Antje Hoering, Ph.D, of Cancer Research And Biostatistics; S. Vincent Rajkumar, M.D., of Mayo Clinic; Muneer H. Abidi, M.D., of Spectrum Health and Michigan State University; Joshua Epstein, DS.c, of University of Arkansas for Medical Sciences; Stephen P. Kahanic, M.D., of Souixland Regional Cancer Center; Mohan C. Thakuri, M.D., of Southeast Clinical Oncology Research Consortium NCORP; Frederic J. Reu, M.D., of Cleveland Clinic; Christopher M. Reynolds, M.D., of Michigan Cancer Research Consortium NCORP; Rachael Sexton, M.S., of Cancer Research And Biostatistics; Robert Z. Orlowski, M.D., Ph.D, of MD Anderson Cancer Center; Bart Barlogie, M.D., Ph.D, of University of Arkansas for Medical Sciences; and Angela Dispenzieri, M.D., of Mayo Clinic. SWOG is a global network of researchers that design and conduct cancer clinical trials, and, as part of the Nation Cancer Institute's National Clinical Trials Network, is a major part of the cancer research infrastructure in the U.S. and the world. The group's goal is to change medical practice so it improves the lives of people with cancer. Founded in 1956, SWOG's 1,300 trials have led to the approval of 14 cancer drugs, changed the standard of cancer care more than 100 times, and saved more than 2 million years of human life. Learn more at swog.org.
News Article | November 21, 2016
Upgrading from competitive systems, Spectrum Health partners with M*Modal to implement a unified and progressive physician documentation strategy for enterprise-wide impact on patient care delivery FRANKLIN, TN--(Marketwired - November 21, 2016) - M*Modal, a leading provider of clinical documentation and Speech Understanding™ solutions, today announced that it has been chosen by Spectrum Health, an award-winning, not-for-profit system with 12 hospitals, 183 ambulatory sites and more than 3,100 physicians, for its speech-driven clinical documentation platform and scalable services. This strategic collaboration will help Spectrum Health streamline documentation workflows and consolidate disparate systems, while enabling its physicians to efficiently and easily document directly in their Cerner (inpatient) and Epic (ambulatory) EHRs. With this forward-thinking, collaborative initiative, Spectrum Health will maximize EHR adoption and usability by breaking existing workflow silos and providing clinicians with a consistent documentation experience, irrespective of how or where they work. M*Modal's cloud-based, unified documentation creation and improvement platform will bring together physicians, nurses, CDI specialists and coders in a cohesive documentation initiative to support Spectrum Health's overarching goal of delivering high-value care. This goal is supported by M*Modal's suite of documentation solutions that bring forward a seamless platform delivering back-end transcription, front-end speech recognition, mobile documentation, Computer-Assisted Physician Documentation (CAPD) and Natural Language Understanding driven CDI workflows. M*Modal's unique documentation system deploys leading-edge, deep learning capabilities to drive even greater accuracy and ease of use while simultaneously providing a risk-sharing economic model with lowest ownership cost. "By partnering with M*Modal, Spectrum Health seeks even greater quality and efficiency in our clinical documentation while driving cost down and physician satisfaction up," said Jason Joseph, senior vice president of information services at Spectrum Health. "M*Modal's robust documentation platform will help us achieve this goal and lay the foundation for future growth and innovation." "We are very pleased to partner with Spectrum Health, an innovative and premier healthcare system, to holistically revitalize its clinical documentation strategy with an adaptable technology framework," said Scott MacKenzie, CEO of M*Modal. "Importantly, our objectives are completely aligned: to reduce the time Spectrum Health physicians spend documenting care and increase the time they spend with their patients delivering care, while simultaneously improving the quality and speed of clinical documentation and communication." The M*Modal platform will be simultaneously deployed across all facilities, in both Cerner and Epic EHR environments, and will provide clinicians and documentation specialists at Spectrum Health with: Flexible Speech Options: The advanced M*Modal speech recognition and Natural Language Understanding (NLU) platform enables physicians to have a superior and personalized documentation experience using real-time speech recognition (Fluency Direct™) and/or a transcription workflow (Fluency for Transcription™), with or without an EHR system. All speech options utilize the same cloud-hosted user profile for improved portability and security so that clinicians can choose the optimal workflow using any device from any location. These interchangeable workflows are further supported by M*Modal's world-class transcription and adoption services. Real-Time CAPD: Fluency Direct is far more than just a front-end speech recognition solution with its automated, embedded CAPD functionality for real-time improvement in documentation quality and patient care. This matchless capability will deliver interactive, in-workflow clinical intelligence to physicians at Spectrum Health as they document in their Cerner and/or Epic EHR systems. The M*Modal closed-loop documentation solution continuously analyzes the note, suggests improvements in quality and compliance, and reports on physician engagement with the system. Intelligence-Driven CDI Workflows: M*Modal's innovative, web-based CDI workflow management solution leverages the company's advanced NLU technology to provide automated abstraction, real-time CDI worklists and game-changing summarized evidence sheets of clinical indicators. These high-value capabilities significantly boost the efficiency of CDI specialists and will help Spectrum Health effectively extend its CDI coverage to all charts and all payers in a very short time. M*Modal is a leading healthcare technology provider of advanced clinical documentation solutions, enabling hospitals and physicians to enrich the content of patient electronic health records (EHR) for improved healthcare and comprehensive billing integrity. As one of the largest clinical transcription service providers in the U.S., with a global network of medical editors, M*Modal also provides advanced cloud-based Speech Understanding™ technology and data analytics that enable physicians and clinicians to include the context of their patient narratives into electronic health records in a single step, further enhancing their productivity and the cost-saving efficiency and quality of patient care at the point of care. For more information, please visit www.mmodal.com, Twitter, Facebook and YouTube.
News Article | April 1, 2016
Dignity Health, Beaumont Health System and Spectrum Health are three companies that have seen benefits from taking up a challenge to reduce chemicals in their health care settings.
News Article | February 27, 2017
Lower stroke, mortality, renal failure, bleeding, atrial fibrillation, and length of intensive care unit stay with newer no-touch technique A landmark study led by Prof. Michael P. Vallely, MBBS, PhD, FRACS, of Sydney Heart and Lung Surgeons and the University of Sydney will be published in the February 28, 2017 issue of the Journal of the American College of Cardiology. According to the study, which involved 37,720 patients, a newer "no-touch" beating heart bypass surgery technique (anOPCABG) reduced postoperative stroke by 78% compared to traditional coronary artery bypass grafting (CABG). In addition, compared to traditional CABG, the newer "no-touch" technique also reduced postoperative mortality by 50%, renal failure by 53%, bleeding complications by 48%, atrial fibrillation by 34%, and length of intensive care unit stay by 13.3 hours. The co-authors of this study included world-renowned cardiothoracic surgeons from Australia, the United States, Canada, and the United Kingdom. Coronary artery bypass grafting (CABG) is a surgical procedure for ischemic heart disease, which is the most common cause of death in Western countries. In this disease, the gradual build-up of fat and calcium within the arteries of the heart causes narrowing, which reduces blood flow to the heart’s muscle. When the narrowing becomes very severe or completely blocked it causes a heart attack. CABG involves bypassing these blockages using a graft. The graft goes around the blocked artery to create new pathway for oxygen-rich blood to flow to the heart again. The aim of this is to relieve symptoms (including angina), help the patient resume a normal lifestyle, and to prevent the risk of heart attacks or other heart problems. However, traditional CABG involves stopping the heart during surgery and placing a clamp on the large vessel of the heart (aorta). Sewing the grafts to the heart is traditionally performed on a still, non-beating heart while the patient is on a heart-lung machine (“on-pump surgery”). In contrast, the newer no-touch, off-pump technique is performed on a beating heart without the heart-lung machine, using a small stabilizer. Since the heart-lung machine is not needed, the large vessels of the heart do not need to be manipulated (an “anaortic” or "no-touch" technique). This technique particularly benefits elderly and high-risk patients, and was shown in this new study to reduce the risk of stroke, death, and kidney injury following the operation. The no-touch beating heart technique performed "without aortic manipulation, whilst performed only by a minority of surgeons, has an important place in the higher risk patient undergoing CABG," commented Prof. Michael P. Vallely, corresponding author of the study and cardiothoracic surgeon at Sydney Heart and Lung Surgeons, "this powerful analysis demonstrates the potential benefit, not only in the reduction of stroke, but also in mortality... [and] provides the most comprehensive and highest-quality evidence currently available [to] help inform decisions regarding the management of these patients." "Interestingly, the risk of stroke seemed to be directly related to the extent of aortic manipulation," said John G. Byrne, MD, of Hospital Corporation of America and Marzia Leacche, MD, of Spectrum Health in an editorial for the Journal of the American College of Cardiology, "a no-touch technique is probably a superior approach compared to conventional on-pump CABG with aortic clamping... in patients with increased cerebrovascular disease or atherosclerotic disease in the aorta." For the first time, an advanced Bayesian network model has been utilized to directly compare the clinical outcomes of all the major coronary artery bypass grafting techniques, including a totally anaortic or “no touch” off-pump technique, off-pump with a partial-clamp, off-pump with the clampless Heartstring device (St. Jude Medical, Saint Paul, Minnesota), and traditional on-pump with cross-clamp technique. This study will be published in the February 28, 2017 issue of the Journal of the American College of Cardiology. Sydney Heart and Lung Surgeons has decades of combined experience in all aspects of adult cardiothoracic surgery. We offer comprehensive patient care, including pre-surgery meetings with the surgeon and daily hospital visits by our surgical team post-operation. Our group treats both private and public patients across Sydney’s major hospitals, including Strathfield Private Hospital, Macquarie University Hospital, Concord Repatriation General Hospital, and the Southern Highlands Private Hospital (Bowral), and are based at Royal Prince Alfred Hospital.
News Article | November 14, 2016
Could a hospital’s digital experience be the new bedside manner? Patients increasingly access healthcare information the same way they do everything else: via search engines and websites, often on their smartphones. Research released this week by Connective DX measures how top clinical hospital systems are meeting the new digital demands of customers and patients. The Hospital Digital Experience (HDX) Index evaluates best practices and benchmarks for hospital system websites, using a rigorous, objective combination of data and observation to assess the top 15 hospital systems as ranked by U.S. News & World Report (2015-2016 Honor Roll). Dave Wieneke, primary researcher and digital strategy director at Connective DX, conducted the research to provide healthcare marketing and technology leaders with an impartial and informed view for improving the digital engagement of their most important audiences. “The website still plays a vital role in supporting a broader patient experience before, during and after they walk through the front door of the hospital,” said Wieneke. “If a patient can’t step through a clear, frictionless, and well-thought out digital experience, what does that say about the hospital’s commitment to patient care when they show up for a procedure?” The research will help hospitals: “The role of digital engagement has fundamentally changed inside healthcare, requiring a shift from building one-off websites and applications to creating connected patient-focused experiences,” said Jeff Cram, chief strategy officer at Connective DX. “This is challenging for many hospitals who haven’t yet established the digital competencies and culture necessary to make the turn.” Although websites are only one point of contact on a continuum of digital patient care, there are several factors that make the report’s focus on public websites particularly valuable. For example, hospital websites are a meaningful part of the overall patient experience, as more than 80% of patients use them to select and plan for care. “We view the hospital’s website as the first step in a digitally-enabled patient experience,” said Patrick O’Hare, CIO of Spectrum Health. “Patients should have one journey of care which incorporates everything we do.” About Connective DX Connective DX is a digital experience agency focused on helping organizations embrace the power of digital, align around the customer, and take control of their digital future. The agency serves clients globally with services that span digital experience strategy, experience design, technology and digital enablement. Founded in 1997, Connective DX has offices in Portland, Ore., and Boston, Mass. Clients include BMC Software, OHSU, KinderCare, Portland General Electric, and many more. https://www.connectivedx.com For more information, press only: Carmen Hill, Connective DX, (503) 972-3579, chill [at] connectivedx [dot] com Laura Brown, Connective DX, (617) 401-2294, lbrown [at] connectivedx [dot] com